Collegium Pharmaceutical Inc. Company Profile

News Articles [ 22 Associated News Articles listed on BioPortfolio]

USPTO issues NOA for Collegium opioid product patent application

The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to Collegium Pharmaceutical's patent application NO.12/823,628 covering a tamper-resistant, extended-release opioid pro...

Collegium Announces Poster Presentation for Oxycodone DETERx, a Tamper-Resistant, Extended-Release Opioid at 6th Annual Pain Therapeutics Summit

Data supporting robust tamper-resistant features of Oxycodone DETERx® CUMBERLAND, R.I.--(BUSINESS WIRE)--Oct 5, 2012 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on...

Collegium Announces Poster Presentation for Oxycodone DETERx, a Tamper-Resistant, Extended-Release Opioid at American Academy of Pain Management's 23rd Annual Clinical Meeting

CUMBERLAND, R.I.--(BUSINESS WIRE)--Sep 27, 2012 - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announc...

Collegium Pharmaceutical's CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013

CANTON, Mass., Feb. 28, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the company's President and CEO, Michael Heffernan, will pres...

Collegium Pharmaceutical to Present at Piper Jaffray's 24th Annual Healthcare Conference

CUMBERLAND, R.I., Nov. 27, 2012 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain,...

Collegium Pharmaceutical to Present at 11th Annual BIO Investor Forum

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain is pleased to announce that Michael Heffern...

Collegium Announces Poster Presentation for Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Opioid at American Pain Society's 32nd Annual Scientific Meeting

CANTON, Mass., May 8, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announc...

Collegium Pharmaceutical's CEO to Present at the UBS Global Health Care Conference in New York on May 20, 2013

CANTON, Mass., May 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present th...

Drugs and Medications [0 Results]

None

PubMed Articles [ 20 Associated PubMed Articles listed on BioPortfolio]

Application of Magnetic Nanoparticles in Pharmaceutical Sciences.

DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population - CORRIGENDUM.

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia - Corrigendum.

Asbestos is still with us: repeat call for a universal ban.

All forms of asbestos are proven human carcinogens. All forms of asbestos cause malignant mesothelioma, lung, laryngeal, and ovarian cancers, and may cause gastrointestinal and other cancers. No expos...

Efficacy of antidepressants: similar but different.

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products target market op...

Collegium Pharmaceutical Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent protected DETERx® formulation pla...